Format

Send to

Choose Destination
See comment in PubMed Commons below
Ai Zheng. 2008 Jan;27(1):30-4.

[Effects of vimentin on invasion and metastasis of prostate cancer cell lines PC-3M-1E8 and PC-3M-2B4].

[Article in Chinese]

Author information

  • 1Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, PR China.

Abstract

BACKGROUND & OBJECTIVE:

Vimentin, a cytoskeleton protein, is involved in regulating the migration and proliferation of cells. This study was to detect the expression of vimentin in prostate cancer cell lines PC-3M-1E8 and PC-3M-2B4, and evaluate the effects of vimentin on invasion and metastasis of prostate cancer cells.

METHODS:

Two-dimensional gel electrophoresis (2-DE) followed by matrix-assisted laser desorption/time of flight mass spectrometry (MALDI TOF-MS) were used to detect the expression of vimentin in prostate cancer cell lines PC-3M-1E8 and PC-3M-2B4. Genetic intervention of vimentin gene and in vitro invasion assay were used to investigate the effects of vimentin on the invasion and metastasis of prostate cancer cells.

RESULTS:

The protein level of vimentin was higher in PC-3M-1E8 cells with high metastatic potential than in PC-3M-2B4 cells with low metastatic potential. Eukaryotic vectors expressing antisense-and sense-vimentin were constructed successfully and transfected into PC-3M-1E8 and PC-3M-2B4 cells separately. The number of invasive cells was significantly lower in PC-3M-1E8/vas cells with antisense-vimentin than in control PC-3M-1E8/3.1(-) cells (99.3+/-4.8 vs. 319.4+/-6.5, P<0.01), and significantly higher in PC-3M-2B4/vs cells with sense-vimentin than in control PC-3M-2B4/3.1(+) cells (330.5+/-5.8 vs. 98.6+/-7.5, P<0.01).

CONCLUSION:

Vimentin is a promising marker for predicting the invasion and metastasis of prostate cancer cells.

PMID:
18184460
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk